Person:
SARIKAYA, UFUK

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
UFUK
Last Name
SARIKAYA
Name
Email Address
Birth Date

Filters

2022 - 20232
Reset filters

Settings

Type: article ×

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    PublicationMetadata only
    Clues to the Harmful Effects of Aspartame on Liver Morphology and Function
    (2022-12-01) Hekimoğlu E. R.; Elibol B.; Toruntay C.; Kırmızıkan S.; Pasin Ö.; Sarıkaya U.; Alkhalidi D.; Eşrefoğlu M.; HEKİMOĞLU, EMİNE RÜMEYSA; KIRMIZIKAN, SEDA; PASİN, ÖZGE; SARIKAYA, UFUK; EŞREFOĞLU, MUKADDES
  • Thumbnail Image
    PublicationOpen Access
    Mass spectrometry-based untargeted metabolomics study of non-obese individuals with non-alcoholic fatty liver disease
    (2023-06-01) Demirel M.; Köktaşoğlu F.; Özkan E.; Dulun Ağaç H.; Gül A. Z.; Sharifov R.; Sarıkaya U.; Başaranoğlu M.; Selek Ş.; DEMİREL, METİN; KÖKTAŞOĞLU, FATMANUR; DULUN AĞAÇ, HALİME; GÜL, AYŞE ZEHRA; SARIKAYA, UFUK; BAŞARANOĞLU, METİN; SELEK, ŞAHABETTİN
    Objectives: Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by the accumulation of excessive fat in the liver, which can lead to fibrosis and has an increasing prevalence. NAFLD requires non-invasive diagnostic biomarkers. While typically observed in overweight individuals, it can also occur in non-obese/non-overweight individuals. Comparative studies on non-obese NAFLD patients are scarce. This study aimed to conduct a using liquid chromatography-high resolution mass spectrometry (LC-MS/MS)-based metabolic profiling of non-obese NAFLD patients and healthy controls. Materials and methods: The patient group consisted of 27 individuals with NAFLD, while the healthy control group included 39 individuals. Both groups were between 18 and 40 years old, had a BMI of less than 25 and had alcohol consumption less than 20 g/week for men and 10 g/week for women. Serum samples were collected and analyzed using LC-MS/MS. The data were analyzed using the TidyMass and MetaboAnalyst. Results: The LC-MS/MS analyses detected significant changes in D-amino acid metabolism, vitamin B6 metabolism, apoptosis, mTOR signaling pathway, lysine degradation, and phenylalanine metabolism pathways in non-obese NAFLD patients. Significant changes were also observed in the metabolites D-pantothenic acid, hypoxanthine, citric acid, citramalic acid, L-phenylalanine, glutamine, and histamine-trifluoromethyl-toluidide, β-hydroxymyristic acid, DL-Lactic acid, and 3-methyl-2-oxopentanoic. Overall, the study provides valuable insights into the metabolic changes associated with non-obese NAFLD patients and can contribute to the development of non-invasive diagnostic biomarkers for NAFLD.